Sort
10,766 grants matching “checkpoint inhibitor”
Investigating conserved mechanisms that orchestrate the prophase to metaphase transition during meiosis I
$65,994Ian Wolff · Cornell University · F32 · FY2021 · HD
Biocompatible strain sensors for continuous monitoring of tumor progression during immunotherapy treatments
$65,994Alex Abramson · Stanford University · F32 · FY2021 · EB
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma
$65,685Cullen Mitsuo Taniguchi · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Analysis of Loss of Function of MAD2 in Mammals
$65,408Sloan-Kettering Institute For Cancer Res · K08 · FY2002 · CA
Analysis of Loss of Function of MAD2 in Mammals
$65,407Loren Scott Michel · Washington University · K08 · FY2006 · CA
Investigating the Role of DNA Repair Mutations in Prostate Cancer Initiation, Progression, and Susceptibility to Targeted Therapies
$65,350Sander Barkley Frank · Fred Hutchinson Cancer Research Center · F32 · FY2019 · CA
Production of Interferon Gamma by Regulatory T Cells Mediates Response to Immunotherapy
$65,310Angela Marie Gocher-Demske · University Of Pittsburgh At Pittsburgh · F32 · FY2020 · CA
DNA Damage and Immunogenicity in Ewing Sarcoma
$65,113Kelly Bailey · University Of Pittsburgh At Pittsburgh · K08 · FY2025 · CA
Clinical Research Program
$65,036Matthew I Milowsky · Univ Of North Carolina Chapel Hill · P30 · FY2023 · CA
Clinical Research Program
$65,036Matthew I Milowsky · Univ Of North Carolina Chapel Hill · P30 · FY2021 · CA
Clinical Research Program
$65,036Matthew I Milowsky · Univ Of North Carolina Chapel Hill · P30 · FY2022 · CA
A Pharmacogenomic Approach Using Precision Models of Hepatocellular Carcinoma to Identify Novel Therapeutics
$64,926Alexander Rialdi · Icahn School Of Medicine At Mount Sinai · F32 · FY2020 · CA
Tumor-derived Exosome Induction of Dendritic Cell Tolerization
$64,926Michael Paul Plebanek · Duke University · F32 · FY2020 · CA
CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
$64,802Arun Rajan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
$64,603Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · U54 · FY2024 · CA
Biocompatible strain sensors for continuous monitoring of tumor progression during immunotherapy treatments
$64,554Alex Abramson · Stanford University · F32 · FY2020 · EB
Project 1: Developing Immune Checkpoint Controlled Release Biomaterials for Caner Immunotherapy
$64,278Richard Mu · Tennessee State University · U54 · FY2024 · CA
Ultrasmall particle-based solutions for inducing ferroptosis and improving anti-tumor immune responses in cancer
$64,250Michelle S Bradbury · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Role of T Regulatory Cell Suppression in Autoimmunity and Cancer
$64,176Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
$64,165Andrew Sikora · University Of Tx Md Anderson Can Ctr · U01 · FY2022 · DE
Cancer Biology Program
$64,076Ann Marie Pendergast · Duke University · P30 · FY2024 · CA
Development of Novel Therapies for HIV Infection
$63,913Robert Yarchoan · Division Of Clinical Sciences - Nci · ZIA · FY2019 · CA
Contribution of sex differences in glioblastoma immune suppression for improved immunotherapy response
$63,746Defne Bayik Watson · Cleveland Clinic Lerner Com-Cwru · F32 · FY2019 · CA
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
$63,718Andrew Sikora · Baylor College Of Medicine · U01 · FY2019 · DE
The Role of Glioma Metabolism in Promoting Tumor Immunosuppression
$63,034Jason Miska · Northwestern University At Chicago · F32 · FY2018 · NS